Anti-cocaine vaccine based on coupling a cocaine analog to a disrupted adenovirus

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 8, 2011, Pages 899-904

  Koob, George ^a   Hicks, Martin J ^b   Wee, Sunmee ^a   Rosenberg, Jonathan B ^b   De, Bishnu P ^b   Kaminksy, Stephen M ^b   Moreno, Amira ^a   Janda, Kim D ^a   Crystal, Ronald G ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Addiction; Adenovirus; Anti cocaine antibody; Cocaine; Passive immunity; Vaccine

Indexed keywords

6 3 (BENZOYLOXY) 8 METHYL 8 AZABICYCLO[3.2.1]OCTANE 2 CARBOXOAMIDO HEXANOIC ACID; ADENOVIRUS VECTOR; BETA GALACTOSIDASE; CAPSID PROTEIN; COCAINE DERIVATIVE; HAPTEN; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG; VACCINE;

ADENOVIRUS 5; ANTIBODY TITER; ARTICLE; COCAINE DEPENDENCE; DRUG EFFICACY; DRUG SEEKING BEHAVIOR; HUMORAL IMMUNITY; HYPERACTIVITY; NONHUMAN; VACCINATION; VIRAL GENE DELIVERY SYSTEM;

EID: 84857751141     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152711799219334     Document Type: Article

References (29)

1. Substance Abuse and Mental Health Services Administration, Anonymous, Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings. Rockville, MD, (Office of Applied Studies, NSDUH Series H-38A, HHS Publication No. SMA 10-4586Findings, 2010.
2. Kinsey, B.M.; Jackson, D.C.; Orson, F.M. Anti-drug vaccines to treat substance abuse. Immunol. Cell Biol., 2009, 87, 309-314.
3. Carrera, M.R.; Ashley, J.A.; Parsons, L.H.; Wirsching, P.; Koob, G.F.; Janda, K.D. Suppression of psychoactive effects of cocaine by active immunization 11. Nature, 1995, 378, 727-730.
4. Carrera, M.R.; Ashley, J.A.; Zhou, B.; Wirsching, P.; Koob, G.F.; Janda, K.D. Cocaine vaccines: antibody protection against relapse in a rat model. Proc. Natl. Acad. Sci. USA, 2000, 97, 6202-6206.
5. Carrera, M.R.; Ashley, J.A.; Wirsching, P.; Koob, G.F.; Janda, K.D. A second-generation vaccine protects against the psychoactive effects of cocaine. Proc. Natl. Acad. Sci., 2001, 98, 1988-1992.
6. Martell, B.A.; Orson, F.M.; Poling, J.; Mitchell, E.; Rossen, R.D.; Gardner, T.; Kosten, T.R. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial 22. Arch. Gen. Psychiatry, 2009, 66, 1116-1123.
7. Haney, M.; Gunderson, E.W.; Jiang, H.; Collins, E.D.; Foltin, R.W. Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol. Psychiatry, 2010, 67, 59-65.
8. Chirmule, N.; Propert, K.; Magosin, S.; Qian, Y.; Qian, R.; Wilson, J. Immune responses to adenovirus and adeno-associated virus in humans 16. Gene Ther., 1999, 6, 1574-1583.
9. Harvey, B.G.; Hackett, N.R.; El-Sawy, T.; Rosengart, T.K.; Hirschowitz, E.A.; Lieberman, M.D.; Lesser, M.L.; Crystal, R.G. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J. Virol., 1999, 73, 6729-6742.
10. Hicks, M.J.; De, B.P.; Rosenberg, J.B.; Davidson, J.T.; Moreno, A.Y.; Janda, K.D.; Wee, S.; Koob, G.F.; Hackett, N.R.; Kaminsky, S.M.; Worgall, S.; Toth, M.; Mezey, J.G.; Crystal, R.G. Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs. Mol. Ther., 2011, 19, 612-619
11. Wee, S.; Hicks, M.J.; De, B.P.; Rosenberg, J.B.; Moreno, A.Y.; Janda, K.D.; Kaminsky, S.M.; Crystal, R.G.; Koob, G.F. Novel cocaine vaccine linked to a disrupted adenovirus gene transfer vector blocks cocaine psychostimulant and reinforcing effects. Neuropsychopharmacology, 2011, [Epub ahead of print].
12. Drug Abuse Warning Network. National Estimates of Drug- Related Emergency Department Visits: 2009. http://www.samhsa.gov/data/2k11/DAWN/2k9DAWNED/HTML/DAWN2k9ED.htm (accessed December 31, 2011).
13. Orson, F.M.; Kinsey, B.M.; Singh, R.A.; Wu, Y.; Kosten, T.R. Vaccines for cocaine abuse. Hum. Vaccin., 2009, I, 194-199.
14. Bagasra, O.; Forman, L.J.; Howeedy, A.; Whittle, P. A potential vaccine for cocaine abuse prophylaxis. Immunopharmacology, 1992, 23, 173-179.
15. Fox, B.S.; Kantak, K.M.; Edwards, M.A.; Black, K.M.; Bollinger, B.K.; Botka, A.J.; French, T.L.; Thompson, T.L.; Schad, V.C.; Greenstein, J.L.; Gefter, M.L.; Exley, M.A.; Swain, P.A.; Briner, T.J. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat. Med., 1996, 2, 1129-1132.
16. Kosten, T.R.; Rosen, M.; Bond, J.; Settles, M.; Roberts, J.S.; Shields, J.; Jack, L.; Fox, B. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine, 2002, 20, 1196-1204.
17. Martell, B.A.; Mitchell, E.; Poling, J.; Gonsai, K.; Kosten, T.R. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol. Psychiatry, 2005, 58, 158-164.
18. Hackett, N.R.; Kaminsky, S.M.; Sondhi, D.; Crystal, R.G. Antivector and antitransgene host responses in gene therapy. Curr. Opin. Mol. Ther., 2000, 2, 376-382.
19. Worgall, S.; Busch, A.; Rivara, M.; Bonnyay, D.; Leopold, P.L.; Merritt, R.; Hackett, N.R.; Rovelink, P.W.; Bruder, J.T.; Wickham, T.J.; Kovesdi, I.; Crystal, R.G. Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses. J. Virol., 2004, 78, 2572-2580.
20. Worgall, S.; Krause, A.; Rivara, M.; Hee, K.K.; Vintayen, E.V.; Hackett, N.R.; Roelvink, P.W.; Bruder, J.T.; Wickham, T.J.; Kovesdi, I.; Crystal, R.G. Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid. J. Clin. Invest., 2005, 115, 1281-1289.
21. Foy, H.M.; Grayston, J.T. Adenoviruses. In: Viral infections of humans: epidemiology and control; Evans, A.S., Ed.; Plenum, Plenum, New York, 1976, pp. 53-69.
22. Koob, G.; Moal, M.L., Eds.; Neurobiology of Addiction. Academic Press, San Diego, CA, 2005.
23. Carrera, M.R.; Ashley, J.A.; Zhou, B.; Wirsching, P.; Koob, G.F.; Janda, K.D. Cocaine vaccines: antibody protection against relapse in a rat model. Proc. Natl. Acad. Sci. USA, 2000, 97, 6202-6206.
24. Epstein, D.H.; Preston, K.L.; Stewart, J.; Shaham, Y. Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure. Psychopharmacology, 2006, 189, 1-16.
25. Yahyavi-Firouz-Abadi, N.; See, R.E. Anti-relapse medications: preclinical models for drug addiction treatment. Pharmacol. Ther., 2009, 124, 235-247.
26. Stewart, J. Pathways to relapse: the neurobiology of drug- and stress-induced relapse to drug-taking. J. Psychiatry Neurosci., 2000, 25, 125-136.
27. Edwards, S.; Whisler, K.N.; Fuller, D.C.; Orsulak, P.J.; Self, D.W. Addiction-related alterations in D1 and D2 dopamine receptor behavioral responses following chronic cocaine self-administration. Neuropsychopharmacology, 2007, 32, 354-366.
28. Kantak, K.M.; Collins, S.L.; Bond, J.; Fox, B.S. Time course of changes in cocaine self-administration behavior in rats during immunization with the cocaine vaccine IPC-1010. Psychopharmacology, 2001, 153, 334-340.
29. Caine, S.B.; Koob, G.F. Effects of dopamine D-1 and D-2 antagonists on cocaine self-administration under different schedules of reinforcement in the rat. J. Pharmacol. Exp. Ther., 1994, 270, 209-218.